Plasmid-mediated, carbapenem-hydrolysing β-lactamase, KPC-2, in Klebsiella pneumoniae isolates

Ellen Smith Moland, Nancy D. Hanson, Vicki L. Herrera, Jennifer A. Black, Thomas J. Lockhart, Ashfaque Hossain, Judith A. Johnson, Richard V. Goering, Kenneth S. Thomson

Research output: Contribution to journalArticle

175 Citations (Scopus)

Abstract

Four isolates of Klebsiella pneumoniae obtained from patients at a Maryland medical centre exhibited reduced susceptibility to carbapenems and were found to produce the novel, class A, plasmid-mediated, carbapenem-hydrolysing enzyme, KPC-2. This enzyme has 99% identity with the plasmid-mediated, carbapenem-hydrolysing enzyme KPC-1, reported previously in a North Carolina K. pneumoniae isolate. The KPC-2-producing isolates were either susceptible or intermediate to imipenem and meropenem, unlike the KPC-1-producing isolate, which was resistant to these agents. Detection of KPC-2 may be a problem for clinical laboratories because in this study it was associated with positive extended-spectrum β-lactamase (ESBL) confirmation tests (clavulanate-potentiated activities of ceftriaxone, ceftazidime, cefepime and aztreonam). Therefore, a failure to recognize the significance of reduced carbapenem susceptibility in the isolates that remained susceptible to imipenem or meropenem could have resulted in the isolates being incorrectly identified as ESBL producers.

Original languageEnglish
Pages (from-to)711-714
Number of pages4
JournalJournal of Antimicrobial Chemotherapy
Volume51
Issue number3
DOIs
StatePublished - Mar 1 2003

Fingerprint

Carbapenems
meropenem
Klebsiella pneumoniae
Plasmids
Imipenem
Enzymes
Aztreonam
Clavulanic Acid
Ceftazidime
Ceftriaxone

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Microbiology

Cite this

Moland, E. S., Hanson, N. D., Herrera, V. L., Black, J. A., Lockhart, T. J., Hossain, A., ... Thomson, K. S. (2003). Plasmid-mediated, carbapenem-hydrolysing β-lactamase, KPC-2, in Klebsiella pneumoniae isolates. Journal of Antimicrobial Chemotherapy, 51(3), 711-714. https://doi.org/10.1093/jac/dkg124

Plasmid-mediated, carbapenem-hydrolysing β-lactamase, KPC-2, in Klebsiella pneumoniae isolates. / Moland, Ellen Smith; Hanson, Nancy D.; Herrera, Vicki L.; Black, Jennifer A.; Lockhart, Thomas J.; Hossain, Ashfaque; Johnson, Judith A.; Goering, Richard V.; Thomson, Kenneth S.

In: Journal of Antimicrobial Chemotherapy, Vol. 51, No. 3, 01.03.2003, p. 711-714.

Research output: Contribution to journalArticle

Moland, ES, Hanson, ND, Herrera, VL, Black, JA, Lockhart, TJ, Hossain, A, Johnson, JA, Goering, RV & Thomson, KS 2003, 'Plasmid-mediated, carbapenem-hydrolysing β-lactamase, KPC-2, in Klebsiella pneumoniae isolates', Journal of Antimicrobial Chemotherapy, vol. 51, no. 3, pp. 711-714. https://doi.org/10.1093/jac/dkg124
Moland, Ellen Smith ; Hanson, Nancy D. ; Herrera, Vicki L. ; Black, Jennifer A. ; Lockhart, Thomas J. ; Hossain, Ashfaque ; Johnson, Judith A. ; Goering, Richard V. ; Thomson, Kenneth S. / Plasmid-mediated, carbapenem-hydrolysing β-lactamase, KPC-2, in Klebsiella pneumoniae isolates. In: Journal of Antimicrobial Chemotherapy. 2003 ; Vol. 51, No. 3. pp. 711-714.
@article{599ad3736b3f488caf992d701d0024f0,
title = "Plasmid-mediated, carbapenem-hydrolysing β-lactamase, KPC-2, in Klebsiella pneumoniae isolates",
abstract = "Four isolates of Klebsiella pneumoniae obtained from patients at a Maryland medical centre exhibited reduced susceptibility to carbapenems and were found to produce the novel, class A, plasmid-mediated, carbapenem-hydrolysing enzyme, KPC-2. This enzyme has 99{\%} identity with the plasmid-mediated, carbapenem-hydrolysing enzyme KPC-1, reported previously in a North Carolina K. pneumoniae isolate. The KPC-2-producing isolates were either susceptible or intermediate to imipenem and meropenem, unlike the KPC-1-producing isolate, which was resistant to these agents. Detection of KPC-2 may be a problem for clinical laboratories because in this study it was associated with positive extended-spectrum β-lactamase (ESBL) confirmation tests (clavulanate-potentiated activities of ceftriaxone, ceftazidime, cefepime and aztreonam). Therefore, a failure to recognize the significance of reduced carbapenem susceptibility in the isolates that remained susceptible to imipenem or meropenem could have resulted in the isolates being incorrectly identified as ESBL producers.",
author = "Moland, {Ellen Smith} and Hanson, {Nancy D.} and Herrera, {Vicki L.} and Black, {Jennifer A.} and Lockhart, {Thomas J.} and Ashfaque Hossain and Johnson, {Judith A.} and Goering, {Richard V.} and Thomson, {Kenneth S.}",
year = "2003",
month = "3",
day = "1",
doi = "10.1093/jac/dkg124",
language = "English",
volume = "51",
pages = "711--714",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Plasmid-mediated, carbapenem-hydrolysing β-lactamase, KPC-2, in Klebsiella pneumoniae isolates

AU - Moland, Ellen Smith

AU - Hanson, Nancy D.

AU - Herrera, Vicki L.

AU - Black, Jennifer A.

AU - Lockhart, Thomas J.

AU - Hossain, Ashfaque

AU - Johnson, Judith A.

AU - Goering, Richard V.

AU - Thomson, Kenneth S.

PY - 2003/3/1

Y1 - 2003/3/1

N2 - Four isolates of Klebsiella pneumoniae obtained from patients at a Maryland medical centre exhibited reduced susceptibility to carbapenems and were found to produce the novel, class A, plasmid-mediated, carbapenem-hydrolysing enzyme, KPC-2. This enzyme has 99% identity with the plasmid-mediated, carbapenem-hydrolysing enzyme KPC-1, reported previously in a North Carolina K. pneumoniae isolate. The KPC-2-producing isolates were either susceptible or intermediate to imipenem and meropenem, unlike the KPC-1-producing isolate, which was resistant to these agents. Detection of KPC-2 may be a problem for clinical laboratories because in this study it was associated with positive extended-spectrum β-lactamase (ESBL) confirmation tests (clavulanate-potentiated activities of ceftriaxone, ceftazidime, cefepime and aztreonam). Therefore, a failure to recognize the significance of reduced carbapenem susceptibility in the isolates that remained susceptible to imipenem or meropenem could have resulted in the isolates being incorrectly identified as ESBL producers.

AB - Four isolates of Klebsiella pneumoniae obtained from patients at a Maryland medical centre exhibited reduced susceptibility to carbapenems and were found to produce the novel, class A, plasmid-mediated, carbapenem-hydrolysing enzyme, KPC-2. This enzyme has 99% identity with the plasmid-mediated, carbapenem-hydrolysing enzyme KPC-1, reported previously in a North Carolina K. pneumoniae isolate. The KPC-2-producing isolates were either susceptible or intermediate to imipenem and meropenem, unlike the KPC-1-producing isolate, which was resistant to these agents. Detection of KPC-2 may be a problem for clinical laboratories because in this study it was associated with positive extended-spectrum β-lactamase (ESBL) confirmation tests (clavulanate-potentiated activities of ceftriaxone, ceftazidime, cefepime and aztreonam). Therefore, a failure to recognize the significance of reduced carbapenem susceptibility in the isolates that remained susceptible to imipenem or meropenem could have resulted in the isolates being incorrectly identified as ESBL producers.

UR - http://www.scopus.com/inward/record.url?scp=0037339196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037339196&partnerID=8YFLogxK

U2 - 10.1093/jac/dkg124

DO - 10.1093/jac/dkg124

M3 - Article

VL - 51

SP - 711

EP - 714

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 3

ER -